ArQule (ARQL) +66% on heavy premarket volume after its experimental lung cancer drug - ARQ 197 -...

|By:, SA News Editor

ArQule (ARQL) +66% on heavy premarket volume after its experimental lung cancer drug - ARQ 197 - shows positive results in a mid-stage trial. In tandem with another lung cancer drug, erlotinib, patients showed a 66% improvement in the time without cancer growth or death. (PR)